Back to results
US 8,278,287 B2Granted
siRNA compounds for inhibiting NRF2
AssigneeQuark Pharmaceuticals, Inc.
InventorsElena Feinstein, Igor Mett, Hagar Kalinski
Life of this patent
Estimating the term…
Abstract
The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
Claims21
A double-stranded compound having the structure:
- 5′ (N)x—Z 3′ (antisense strand)
- 3′ Z′—(N′)y—Z″ 5′ (sense strand)
- wherein each of N and N′ is a nucleotide which may be an unmodified or a modified ribonucleotide, or may be an unconventional nucleotide moiety;
- wherein each of (N)x and (N′)y is an oligonucleotide in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
- wherein Z and Z′ may be present or absent, but if present is independently 1-5 consecutive nucleotides covalently attached at the 3′ terminus of the strand in which it is present;
- wherein Z″ may be present or absent, but if present is a capping moiety covalently attached at the 5′ terminus of (N′)y;
- wherein x=y=19;
- wherein (N)x comprises at least five alternating unmodified and modified ribonucleotides beginning at the 3′ end of (N)x and at least nine modified ribonucleotides and unconventional nucleotide moieties in total and each remaining N is an unmodified ribonucleotide;
- wherein (N′)y comprises an unconventional nucleotide moiety which is selected from the group consisting of an L-DNA mirror nucleotide and a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond in at least one of the 3′ terminal position or the 3′ penultimate position;
- and
- wherein the sequence of (N)x is 5′ UUGUCAUCUACAAACGGGA 3′ (SEQ ID NO:
- 8,506) and the sequence of (N)y is 5′ UCCCGUUUGUAGAUGACAA 3′ (SEQ ID NO:
- 8,497).
10 more elements
Dependencies are inferred from the claim text.